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Introduction
Febrile neutropenia (FN) is a condition marked by
fever developing in patients suffering from neutropenia.
The fever is caused by infection in 50% of cases and
bacteremia may be present in as many as 20% of the
patients with an absolute neutrophil count under 1,000
cells/ mcL (mm3) (Hughes et al., 2002). According to the
Infectious Disease Society of America (IDSA) and the
US Food and Drug Administration (FDA), a single
temperature ≥38.3°C (1010F) orally or a temperature of
38.0°C (100.40F) over 1 hour in the absence of an obvious
cause, is defined as fever and ≤500 neutrophils/mcL or
≤1,000 neutrophils/mcL and a predicted decline to 500/
mcL over the next 48 hours is defined as neutropenia
(Hughes et al., 2002).
FN is causally associated with myelosuppressive
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Abstract
Introduction: Febrile neutropenia (FN) is a major complication of chemotherapy, costly in terms of morbidity,
mortality and associated financial expenditure. The present study was conducted with the goal of highlighting
FN as a serious problem in Pakistan, with the longer term objective of improved cancer survival, reduction in
length of stay (LOS) in hospital, morbidity, mortality and costs in our existing developing country scenario.
Methods: A cross-sectional descriptive study was conducted on patients, ≥18 years, admitted with FN as a
consequence of chemotherapy at a referral hospital in Karachi from 1st September 2006 to 30th April 2007.
Results: A total of 80 patients [43 (53.8%) males and 37 (46.2%) females] were selected. The mean age was 47.4
(SD ±16.6; range 18-79) years. Sixty eight patients (86%) were ≤ 65 years, 50% were ≤ 50 years. Overall, in-
hospital mortality was 11%; 4% for patients on granulocyte colony stimulating factor (G-CSF) prophylaxis as
against 20% for those without. The cause of death was either pneumonia or septic shock. Mean LOS was 7.53
(SD ±3.8; range 2-17) days. Hematological malignancies, older age, severity of dehydration, pneumonia and
culture positivity were significantly associated with LOS and death. Those above 50 years of age were 1.5 times
as likely to be hospitalized longer and > three times as likely to die. Bacteremia conferred a 5-fold and pneumonia
an 8-fold increase in the risk of death. Conclusion: The results of this study indicate that age, vital instability,
dehydration, high creatinine, culture positivity and hematological malignancies are high risk factors in
chemotherapy induced FN. Identification of FN risk factors with poor outcomes may help in devising protocols
for modified dosage or including GCFs initially. This may help reduce the cost of cancer care as well as mortality
and morbidity. Prospective studies of FN in multiple centers in Pakistan may be beneficial in evaluating these
risk factors further.
Key Words: Febrile neutropenia - cancer patients - in-hospital stay - mortality - Pakistan
chemotherapy in adults. Affected patients are empirically
treated with antibiotics until the neutrophil count has
recovered. Guidelines issued in 2002 by IDSA recommend
the use of combinations of antibiotics in specific settings;
mild low-risk cases may be treated with a combination of
oral co-amoxiclav and ciprofloxacin, while more severe
cases require cefalosporins with activity against
Pseudomonas aeruginosa (e.g. ceftazidime), or
carbapenems (imipenem or meropenem) (Hughes et al.,
2002). Excluding infection, the other causes of fever in
cancer patients are, tumor-associated factors, allergic or
hypersensitivity reaction to drugs especially amphotericin,
biologics and some cytotoxic agents and allergic or
hypersensitivity reactions to blood component therapies
(Hughes et al., 2002).
FN is costly in terms of morbidity, mortality and
associated financial expenditure. A number of different
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models based on the characteristics demonstrated by
patients at onset of febrile neutropenia have been designed
to enable clinicians to assign patients to high or low-risk
groups thus attempting to identify patients with the greatest
chance of recovering without serious medical
complication and also those who might encounter difficult
sequels (Talcott et al., 1988).
The Multinational Association of Supportive Care in
Cancer (MASCC) risk-index score identifies low-risk
patients (score ≥21 points) at the onset of FN. These
patients are at a risk of developing serious complications
of FN (including death, intensive care unit admission,
confusion, cardiac, renal and respiratory failure,
hypotension and hemorrhage (Klastersky J et al, 2000). It
also helps to establish the current guidelines for the
treatment of FN by the IDSA as well as the
recommendations for the use of hematopoietic colony-
stimulating factors (CSFs) by the American Society of
Clinical Oncology (ASCO) (Klastersky et al., 2000; Basu
et al., 2005).
The main objective of this study was to highlight FN
as a serious complication of chemotherapy, identify risk
factors, appreciate established FN guidelines, use them
for prophylaxis and to predict outcomes especially in our
setup in terms primarily of length of hospital stay (LOS)
and mortality associated with FN and thus improve patient
survival.
Materials and Methods
This study was designed as a cross-sectional
descriptive study. All patients, 18 years and above, who
had a biopsy proven cancer, been exposed to
chemotherapeutic agent/s, found febrile (>38˚C) and
neutropenic (below 500 cells/µL) were included in the
study. Patients in the setting of immunodeficiency status
or neutropenia associated with syndromes that are not
associated with a high risk of bacterial infection (e.g.
chronic benign neutropenia) were excluded from the study.
The major outcomes of interest were length of stay
(LOS) in hospital and mortality. The major independent
variables of interest were age, sex, histopathologic
diagnosis, associated complications, co-morbid
conditions, clinical presentation including severity of
dehydration, oral mucositis, hematological and
biochemical changes including severity of neutropenia in
cancer patients with chemotherapeutic induced febrile
neutropenia.
Patients of FN who were admitted from 1st September
2006 to 30th April 2007 at the Section of Medical
Oncology and Hematology, Department of Medicine, the
Aga Khan University Hospital, Karachi were recruited
for the study, after obtaining written informed consent.
At admission, all eligible patients with FN had a detailed
history and examination by the admitting residents. Blood
was drawn for Complete Blood Count (CBC), creatinine,
serum electrolytes, Liver Function Tests (LFTs), blood
culture and sensitivity (C/S) from the peripheral veins and
also from the central venous access devices (Port-A-cath,
Hickman Line, Central Venous Line).
Urine culture and chest X-rays were taken and in
selected patients ultrasonography was done to identify the
source of infection and also to identify the disease severity.
Empirical intravenous antibiotics were started after
drawing blood and urine cultures. Every patient was
followed throughout the length of hospital stay. Data
collection forms were used to collect data regarding
demographics, laboratory parameters, cancer type, co-
morbid medical illnesses and complications and LOS
along with outcome (discharged, died, left against medical
advice).
The primary outcomes of this analysis were LOS and
mortality in the hospital, which served as markers for the
severity of illness. Univariate association between each
outcome variable (length of stay and mortality) and each
of the independent variables was then evaluated. Length
of stay was used as a dichotomous variable (≤5 days and
> 5 days) for the purpose of the initial univariate analyses.
The cut-off point of 5 days for the purpose of the analysis
was determined before the data analysis and was based
on the clinical expectation that a patient who was admitted
for less than 5 days most likely represented one who had
an uncomplicated disease-course in the hospital.
Results
A total of 80 patients [43 (53.8%) males and 37
(46.2%) females] were selected for the study using the
criteria described in the methodology. The mean age was
47.4 (95%CI 43.66, 51.06; SD 16.6; range 18-79) years.
Sixty eight patients (86%) were ≤ 65 years and 50% were
≤ 50 years of age. The majority of the patients hailed from
Karachi (65, 81.3%), however 14 (17.5%) were residents
of other regions of Pakistan and 1 (1.2%) patient came
from Kabul, Afghanistan.
The topographic distribution of tumors according to
the primary site was - solid tumors (29 cases, 37.5 %) and
hematological malignancies (51 cases, 63.8%). The
distribution of solid cancers was breast cancer (17 cases,
58.6%), ovarian cancer (4 cases, 13.8%), gastric cancer,
lung cancer, and Ewing’s sarcoma (2 cases, 6.9%) each
and uterine cancer and immature teratoma (1 case, 3.45%)
each. The sub-distribution of hematological malignancies
was non-Hodgkin’s lymphoma, NHL (30 cases, 58.8%),
Table 1. Frequencies of Predictor Variables
Frequency Percentage
Temperature
<38˚C/≥38˚C 16/64 20.0/80.0
Pulse rate
≤80/≥80 14/66 17.7/82.3
Hemoglobin
<10/10 & above 34/46 21.5/58.5
Platelet
<50/ 50 & above 20/60 25.0/75.0
Platelet??
<20/20 & above 12/68 15.0/85.0
ANC
<100/100 and above 64/16 80.0/20.0
S. Creatinine
<1/1 and above 71/9 88.9/11.1
Total   80               100.0
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acute myeloid leukemia (AML) and acute lymphoid
leukemia (ALL) 7 (13.7%) cases each,  multiple myeloma
(MM) 3 (5.88%) cases, Hodgkin’s lymphoma (HD),
chronic lymphoid leukemia (CLL), chronic myeloid
leukemia (CML) and follicular lymphoma (FL) 1 (1.96%)
case each. Metastatic disease was seen in 33 (41.3%) cases
whereas 47 (58.8%) patients had localized disease.
Twenty five (31.5%) patients had one or more co-
morbids. The co-morbid conditions were diabetes mellitus
(DM), chronic renal failure (CRF), and DM with CRF (9
cases, 11.3%) each, COPD and hypothyroidism 1 (1.3%)
case each. On admission, 30 (37.5%) subjects had severe
dehydration, 10 (12.5%) had abnormal creatinine levels,
17 (21.3%) had severely abnormal ANC, 31 (38.8%) had
a low hemoglobin and 20 (25.0%) had a low platelet count.
There were 21 (26.3%) patients with a positive blood
culture and 25 (20.0%) subjects with pneumonia (Table
1).
The mean LOS was 7.53 (95%CI 6.67, 8.83; SD 3.8;
range 2-17) days. The study sample consisted of 29
(36.3%) patients with a length of stay of 5 days or less
and 31 (63.7%) patients with length of stay longer than 5
days. The mean and median length of stay for the patients
admitted for 5 days or less were the same (3 days), with a
range of 1 to 5 days. The mean and median length of stay
for the patients admitted for longer than 5 days were 19
days and 12 days, respectively, with a range of 6 to 359
days.
Patients had been febrile for 1.48 (95%CI 1.31, 1.64;
SD .75; range 1-3) days at the time of admission and
neutropenic for 1.84 (95%CI 1.67, 2.01; SD .77; range 1-
3) days. An average of 10.28 (95%CI 8.14, 12.41; SD
9.6; range 2-87) days had elapsed since the patients started
chemotherapy. An average of 5.26 (95%CI 3.62, 6.89; SD
7.3; range 1-36) months had elapsed since the patients
had been diagnosed with cancer. Thirty five patients
(43.8%) had taken prophylactic antibiotics within the past
7 days before developing FN whereas 45 (56.3%) of the
patients were not on antibiotic cover. Forty five (56.3%)
patients were on G-CSF prophylaxis.
As seen in Table 2, patients with a hematological
malignancy were found to be at a greater risk of being
hospitalized for longer than 5 days as compared with
subjects with solid cancer. Similarly patients with severe
dehydration, low hemoglobin, positive blood culture and
pneumonia were also significantly more likely to have a
longer length of stay as compared with subjects without
these associated conditions (Table 2).
Nine patients died in the study, leading to a mortality
of 11.3%. Four percent of the patients on G-CSF
prophylaxis died of complications associated with FN as
against 20% of those without G-CSF cover. The cause of
death was either pneumonia or septic shock. Patients with
hematological malignancies, those who were severely
dehydrated those with positive blood cultures and
pneumonia had an increased risk of death, as seen in Table
3. After controlling for cancer type and complications the
elderly group were almost 1.5 times as likely to be
hospitalized longer and more than three times as likely to
die as the younger group below 50 years of age. Vital
instability, severity of dehydration and bacteremias were
Total 7.53 (3.83)
Table 3. Bivariate Association between Each Predictor
Variable and Mortality
          Yes*     No*      Odds Ratio (95% C.I.)   p-value
Solid/Liquid Tumor 0.263
Solid 2 29 1
Liquid 7 42 2.42 (0.47, 12.5)
Severely abnormal ANC 0.370
Yes 3 14 0.49 (0.11, 2.21)
No 6 57 1
Severity of Dehydration 0.059
Normal/Mild 3 47 1
Mod/Severe 6 24 3.92 (0.90, 17.04)
ER Creatinine 0.298
<1 4 54 1
1 or more 3 17 2.38 (0.48, 11.7)
Blood Culture 0.032
Positive 6 21 4.76 (1.09, 20.9)
Negative 3 50 1
Pneumonia on Chest X-ray 0.005
Yes 6 14 8.14 (1.81, 36.7)
No 3 57 1
Hb Level in Emergency/OPD 0.279
<10 5 26 2.16 (0.53, 8.78)
10 & above 4 46 1
Platelet Level in Emergency/OPD 0.551
<50 3 17 1.59 (0.36, 7.04)
50 & above 6 54 1
*Death within one month 1 – reference category
Table 2. Bivariate Association between Each Predictor
Variable and Length of Stay
Factor           Mean (SD)   Difference    95% C.I.      p-value
Solid/Liquid
Solid   6.0 (3.5)
Liquid   8.5 (3.8) -2.5 -4.2, -0.8 0.004
Co-Morbidity
Yes   7.3 (3.9)
No   7.6 (3.8)  0.3 -1.5, 2.2 0.702
Taken Prophylactic
Yes   7.0 (4.0)
No   7.9 (3.7) -0.9 -2.7, 0.8 0.283
Severely abnormal ANC
Yes   8.8 (4.1)
No   7.2 (3.7) -1.6 -3.7, 0.4 0.116
Severity of Dehydration
Normal-Mild   5.2 (2.2)
Mod-Severe 11.4 (2.7) -6.2 -7.3, -5.0 <0.001
ER Creatinine
<1   7.1 (4.0)
1 or more   8.9 (3.4) -1.8 -3.7, 0.2 0.079
Blood Culture
Positive   6.3 (3.4)
Negative 10.0 (3.5) -3.7 -5.3, -2.1 <0.001
Pneumonia on Chest X-ray
Yes   9.7 (4.0)
No   6.8 (3.5) -2.9 -4.7, -0.96 0.004
Hb Level in ER
<10   8.6 (3.6)
10 & above   6.8 (3.8)  1.8 0.06, 3.5 0.043
Platelet Level in ER
<50   8.5 (4.1)
50 & above   7.2 (3.7)  1.3 -0.7, 3.3 0.191
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significantly associated with both longer LOS and
mortality. A diagnosis of bacteremia conferred a 5-fold
increase in the risk of death. Pneumonia was associated
with an eight-fold increase in the risk of death.
Discussion
Poor cancer survival has been lamented in Karachi
and largely in Pakistan, whereby a large number of cancer
patients die within the first year of diagnosis (Bhurgri et
al., 2004). One of the causes of early mortality is FN, a
life-threatening infection, associated with lengthy
hospitalization and high morbidity and medical costs. In
addition, neutropenia is the primary cause of dose
reductions and dose delays, limiting the delivery of the
chemotherapy at full dose, on schedule, thus further
compromising long-term survival in patients with
potentially curable malignancies. The overall goal of this
study was to better understand factors associated with
outcomes of FN. The objective being improved cancer
survival, reduction in LOS, morbidity, mortality and if
possible costs in our existing developing country scenario.
In the present study FN emerges as a high mortality
complication of myelosuppressive chemotherapy. The
elderly, those with hematological malignancies, the
severely dehydrated patients, those with positive blood
cultures and pneumonia were at an increased risk of longer
LOS and death. Bacteremia conferred a 5-fold increase
and pneumonia an eight-fold increase in the risk of death.
These findings collaborate with other published studies.
In comparison to solid tumors, a diagnosis of
hematological malignancies particularly AML and NHL
was associated with a three-fold increased risk of longer
LOS as well as mortality. A diagnosis of breast cancer
and ovarian cancer was associated with a significant
reduction in the risk of both. The severity of neutropenia
and abnormal creatinine were significantly associated with
both longer LOS and mortality.
In studies of adults with febrile neutropenia, older age
has emerged as a significant risk factor for poor outcomes
(Morrison et al., 2001). Other factors associated with
increased mortality, LOS and cost in hospitalized adult
cancer patients with FN include patient characteristics,
type of malignancy, co-morbidities, and infectious
complications. Recognition of these factors may be useful
in identifying patients at increased risk of serious medical
complications and mortality for more aggressive
supportive care measures (Kuerer et al., 2006). Many
recent studies have documented that the greatest risk of
neutropenia and its complications is in the first cycle of
chemotherapy, whence > 50% of the first episodes of
neutropenia and FN occur (Ozer, 2006; Ray-Coquard et
al., 2006). FN also occurs more commonly during the first
few days of each subsequent cycle of chemotherapy. Thus
a better initial predictive approach may allow better
therapeutic decisions for these patients, with an eventual
impact on reducing mortality (Vincenzino, 1995).
There is a trend towards prophylactic, empirical use
of antibiotics including Ceftriaxone and Amikacin for
febrile neutropenia, oral Itraconazole for antifungal
prophylaxis and oral acyclovir for antiviral prophylaxis
(Shamsi et al., 2004). There is also an increasing trend of
gram negative organisms developing resistance to
commonly used antibiotics. Gram positive bacteria are
also showing emerging resistance to vancomycin (Khan
et al., 2004). In recent years, there has been increasing
interest in stratifying patients with FN into risk categories
to explore various therapeutic strategies (Talcott et al.,
1988; Klastersky et al., 2000; Ozer et al., 2000; Basu et
al., 2005). Granulocyte colony-stimulating factors (G-
CSFs) have been shown to help prevent febrile neutropenia
in certain subgroups of cancer patients undergoing
chemotherapy, but their role in treating febrile neutropenia
is controversial (Rocio García-Carbonero et al, 2001). The
use of pegfilgrastim from the first cycle has been shown
to reduce the incidence of febrile neutropenia in patients
receiving moderately myelosuppressive chemotherapy
and may be particularly beneficial in elderly patients
(Weber, 1993; Balducci and Lyman, 2001; Chrischilles
et al., 2002; Bennett and Schumock, 2003; Lyman et al.,
2003; Repetto et al., 2003; Lyman, 2005; Caggiano et al.,
2005).
Management of FN remains a costly challenge.
Chemotherapy-related hematological adverse effects
globally result in a substantial economic burden on
patients, payers, caregivers and society in general (Liou
et al., 2007). In Pakistan, a country of low to medium
economic resource, which is not a welfare state, there is a
substantial economic burden on cancer patients and
caregivers especially the elderly. Employers do not bear
the responsibility of treatment costs, moreover the
retirement age is 60 years, there are little health related
retirement benefits and the concept of health insurance is
nonexistent. In the past, there have been attempts to
identify patients who could be managed in an outpatient
basis to save the cost incurred during inpatient
management. Malik et al compared out-patient treatment
with an oral antibiotic (ofloxacin) to in-patient treatment
with this same antibiotic in patients experiencing
neutropenia of short duration. A considerable proportion
(21%) of their subjects receiving oral antibiotic treatment
as out-patients required hospitalization and this group had
a 4% mortality rate, raising concerns about the safety of
this approach (Malik et al., 1995).
Delayed hospitalization remains an associated problem
in the management of FN either due to avoidance of costs
or a failure to recognize FN as a serious complication. In
our study conducted at a major referral centre, the patients
had been febrile and neutropenic for approximately 2 days
at the time of admission and had been on chemotherapy
for atleast 10 days. The delay in referral compounds the
problem of FN management, as patients report in a critical
state, the mortality in our study being 11.25%. In the
present study, those subjects who were on G-CSF
prophylactic cover had a lower mortality from FN. Most
studies support the finding that adding G-CSF to antibiotic
therapy shortens the duration of neutropenia, reduces the
duration of antibiotic therapy and hospitalization, and
decreases hospital costs in patients with high-risk febrile
neutropenia. The therapeutic role of G-CSF in LOS and
mortality could not be studied as all patients were given
Asian Pacific Journal of Cancer Prevention, Vol 9, 2008 307
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neutropenia and cancer. Additional information regarding
socioeconomic status and delay in treatment could be
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treating all FN neutropenic patients with empiric broad-
spectrum antibiotics for potential bacteremia, FN with
cancer remains associated with a significant, mortality
rate. This suggests that certain host or disease-related
factors may play a role in influencing mortality resulting
from FN.
The results of this study indicate that age, vital
instability, dehydration, neutropenia, high creatinine,
culture positivity and hematological malignancy should
be considered high risk factors in chemotherapy induced
FN cancer patients. The identification of risk factors for
poor outcomes may help in devising protocols for
modified dosage or including GCFs initially. This may
help reduce the cost of cancer care as well as reduce
mortality and morbidity. Prospective studies of FN among
chemotherapy induced cancer patients in multiple centers
in Pakistan may be beneficial in evaluating these risk
factors further.
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